Browsing Tag
RNA-targeted therapy
2 posts
Can zilganersen become the first disease-modifying therapy for Alexander disease?
Ionis wins FDA breakthrough therapy status for zilganersen in Alexander disease. Find out what this means for rare neurology drug development.
Ionis Pharmaceuticals moves forward with FDA review of donidalorsen for HAE
In a significant development for hereditary angioedema (HAE) patients, Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S.…